CTC Bio씨티씨바이오
060590 · KOSDAQ · ₩060590 · 씨티씨바이오
₩2,585▼ ₩50 (1.90%)End-of-day · Oct 30, 2026 · End-of-day prices.
Margins
| TTM | 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|---|
| Gross margin | 42.6% | 40.7% | 36.9% | 31.2% | 33.2% | 23.9% |
| Operating margin | 9.4% | 5.0% | −2.7% | −3.3% | 7.1% | −2.1% |
| Net margin | 6.1% | 2.6% | −3.6% | −11.3% | 4.1% | −5.2% |
Growth (year on year)
| TTM | 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|---|
| Revenue growth | −1.1% | −14.3% | +4.7% | −16.5% | +17.7% | — |
| Operating income growth | +83.3% | +258.1% | +13.7% | −139.1% | +498.8% | — |
| Net income growth | +131.9% | +162.1% | +66.5% | −330.9% | +192.3% | — |
Returns
| TTM | 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|---|
| Return on equity | 9.9% | 4.6% | −7.2% | −18.2% | 7.5% | −8.6% |
| Return on assets | 3.2% | 2.2% | −3.3% | −8.8% | 3.4% | −4.7% |
Leverage and liquidity
| TTM | 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|---|
| Liabilities to equity | 90.6% | 97.0% | 120.8% | 119.8% | 95.8% | 97.9% |
| Net debt to equity | 4.7% | 12.1% | 12.9% | 8.5% | 10.3% | 31.9% |
| Current ratio | 156.1% | 137.8% | 111.1% | 113.2% | 120.3% | 117.5% |
Calculated from filed financial statements. TTM = trailing 12 months.
Also known as: CTC Bio / 씨티씨바이오 / 060590 / KRX:060590
Source: KRX statistical information